Quality of Life during Treatment with Lenvatinib for Thyroid Cancer: The Patients’ Perspective beyond the Medical Evaluation | Zendy

Alice Nervo | Zendy; Alberto Ragni | Zendy; Alessandro Piovesan | Zendy; Valentina Marica | Zendy; Enrica Migliore | Zendy; Marco Gallo | Zendy; Emanuela Arvat | Zendy

Open Access

Quality of Life during Treatment with Lenvatinib for Thyroid Cancer: The Patients’ Perspective beyond the Medical Evaluation

Author(s) -

Alice Nervo,

Alberto Ragni,

Alessandro Piovesan,

Valentina Marica,

Enrica Migliore,

Marco Gallo,

Emanuela Arvat

Publication year - 2020

Publication title -

european thyroid journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.23

H-Index - 10

eISSN - 2235-0802

pISSN - 2235-0640

DOI - 10.1159/000508186

Subject(s) - medicine , quality of life (healthcare) , common terminology criteria for adverse events , adverse effect , visual analogue scale , lenvatinib , clinical trial , population , refractory (planetary science) , thyroid cancer , physical therapy , cancer , physics , nursing , environmental health , astrobiology

Lenvatinib (LEN) has shown great efficacy but important toxicity in patients with advanced radioactive iodine-refractory (RAI-R) thyroid cancer (TC); a focused evaluation of its impact on patients' quality of life (QoL) is still lacking. Our prospective study investigated the impact of this drug on QoL in a group of RAI-R TC patients treated at our centre.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research